Cell Cure Neurosciences was founded based on cutting edge technology from Hadassah University Hospital’s Human Embryonic Stem Cell Research Center and the Departments of Ophthalmology and Neurology. Cell Cure’s R&D activities are currently carried out by a team of 15 scientists with laboratories located on the campus of Hadassah University Hospital in Jerusalem, Israel.
Dr. Irving serves as CEO of Cell Cure Neurosciences. He holds a Ph.D. in Chemistry from the Weizmann Institute of Science. Before switching from academia to biotech product development, Dr. Irving was an Associate Professor in the Department of Pediatrics, Baylor College of Medicine, Houston TX. Dr. Irving brings to Cell Cure Neurosciences valuable managerial skills, having been COO of a subsidiary of a US medical device company for nine years, as well as Vice President of Clinical and Regulatory Affairs and VP of Business Development of an Israeli start-up medical device company. Dr. Irving’s management experience also includes leading another Israeli biotech company from the stage of in-licensing academic technology through cGMP production to Phase I/II clinical trials and the successful out-licensing of its biologic product.
Prof. Reubinoff serves as CSO of Cell Cure Neurosciences. He received his M.D. degree from the Hebrew University – Hadassah Medical School, Jerusalem, Israel. He completed his residency in Obstetrics and Gynecology at the Hadassah Medical Center. Prof Reubinoff also holds a PhD degree in developmental biology from Monash University, Melbourne, Australia. Prof. Reubinoff has been the Chief Scientific Officer at Cell Cure Neurosciences since 2006. Currently, Prof. Reubinoff is a full Professor of Obstetrics and Gynecology and serves as Chairman of the Department of Obstetrics and Gynecology. He is also the director of the Hadassah Human Embryonic Stem Cell Research Center.
The major focus of Prof. Reubinoff’s research has been on human embryonic stem cells (hESCs). Professor Reubinoff derived hESC in collaboration with scientists from Monash University in Melbourne and the National University of Singapore. The group was the second in the world to derive hESC lines and was the first to show somatic differentiation of the hESCs in culture.
Professor Banin is a key advisor at Cell Cure Neurosciences and is Head of Degenerative Diseases of Retina and Macula and an expert in the field of cell therapy for retinal and macular degenerations.